IMC-2032 is under clinical development by ImmuneCyte and currently in Phase I for Premature Ageing. According to GlobalData, Phase I drugs for Premature Ageing does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the IMC-2032 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IMC-2032 overview
IMC-2032 is under development for the treatment of premature ageing and beta thalassemia. The therapeutic candidate is developed based on proSTEM platform.
ImmuneCyte overview
ImmuneCyte, a subsidiary of HealthBanks Biotech (USA) Inc, is a biopharmaceutical company that includes research and development of cell and gene therapies for cancer, vascular, orthopedic and aging-related diseases. It is investigating drugs against critical limb ischemia (CLI) and diabetic foot ulcer (DFU); orthopedic diseases including osteoarthritis, non-union fracture, avascular necrosis and spinal fusion. The company is also evaluating programs for the treatment of premature aging, premature ovarian failure, non-Hodgkin lymphoma, multiple myeloma, melanoma, metastasized breast cancer, renal cell carcinoma and other immune-oncology and hematology indications. ImmuneCyte utilizes its proprietary CARTXpress manufacturing platform to develop cell-based immunotherapies. It operates with an additional office in Tianjin, China. ImmuneCyte is headquarter in Irvine, California, the US.
For a complete picture of IMC-2032’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
